澳大利亚生物技术巨头CSL周四表示，该公司在维多利亚州最高法院面临一起股东集体诉讼，原告指控其违反了持续披露义务，涉及财务预测。
Australia's CSL faces investor proceeding over disclosure obligations Oct 22 - CSL said on Thursday it had been hit with a shareholder class action in Victoria's Supreme Court, alleging the Australian biotech giant breached its continuous disclosure obligations over financial forecasts.
该集体诉讼由律所Echo Law提起，代表在2025年2月11日至2026年5月11日期间购买特定CSL证券的投资者。
The class action, filed by law firm Echo Law, was commenced on behalf of investors who acquired certain CSL securities between February 11, 2025, and May 11, 2026.
Echo Law在其网站声明中称：“指控涉及公司的中期指引和2026财年指引，这两项指引均在索赔期间被撤回或下调，以及在2024年和2025年免疫球蛋白和白蛋白产品市场条件变化的背景下，该指引的合理性。”CSL表示否认任何责任，并将对该诉讼进行抗辩。
"The allegations relate to the company's medium-term and FY26 guidance, both of which were retracted or downgraded during the claim period, and the reasonableness of the guidance in the context of changes to market conditions for immunoglobulin and albumin products in 2024 and 2025," Echo Law said in a statement on its website. CSL said it denied any liability and would defend the proceeding.